Table 3.
Proportion of subjects in the multidose study with a clinically meaningful increase in hemoglobin anytime between baseline and the end of study or time of intervention.
| SMC subgroup | ||||
|---|---|---|---|---|
| FCM | Venofer or Ferrlecit | Oral iron | Other treatment | |
| N = 293 | N = 103 | N = 152 | N = 42 | |
| n (%) | ||||
| 187 (64) | 59 (57) | 68 (45) | 22 (52) | |
| Difference from FCM 95% CI |
0.07 (−0.05, 0.18) |
0.19 (0.09, 0.29) |
0.11 (−0.06, 0.29) |
|
| n/N (%) | ||||
|
| ||||
| IDA Etiology | ||||
| CKD | 15/34 (44) | 8/16 (50) | 2/11 (18) | 1/4 (25) |
| Heavy uterine bleeding | 55/71 (78) | 16/25 (64) | 25/52 (48) | 8/11 (73) |
| IBD/GI related | 41/61 (67) | 19/25 (76) | 4/15 (27) | 7/15 (47) |
| Postpartum | 16/24 (67) | 0 | 8/18 (44) | 1/1 (100) |
| Other/Unknown | 60/103 (58) | 16/37 (43) | 29/56 (52) | 5/11 (45) |
FCM: ferric carboxymaltose; IDA: iron deficiency anemia; SMC: standard medical care.